Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.

Orkin C, Squires KE, Molina JM, Sax PE, Wong WW, Sussmann O, Kaplan R, Lupinacci L, Rodgers A, Xu X, Lin G, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C, Martin EA; DRIVE-AHEAD Study Group.

Clin Infect Dis. 2019 Feb 1;68(4):535-544. doi: 10.1093/cid/ciy540.

2.

14-3-3γ binds regulator of G protein signaling 14 (RGS14) at distinct sites to inhibit the RGS14:Gαi-AlF4- signaling complex and RGS14 nuclear localization.

Gerber KJ, Squires KE, Hepler JR.

J Biol Chem. 2018 Sep 21;293(38):14616-14631. doi: 10.1074/jbc.RA118.002816. Epub 2018 Aug 9.

PMID:
30093406
3.

Decoding: It's Not All About the Letters.

Squires KE.

Lang Speech Hear Serv Sch. 2018 Jul 5;49(3):395-408. doi: 10.1044/2018_LSHSS-17-0104.

PMID:
29978208
4.

Genetic Analysis of Rare Human Variants of Regulators of G Protein Signaling Proteins and Their Role in Human Physiology and Disease.

Squires KE, Montañez-Miranda C, Pandya RR, Torres MP, Hepler JR.

Pharmacol Rev. 2018 Jul;70(3):446-474. doi: 10.1124/pr.117.015354. Review.

PMID:
29871944
5.

Regulator of G protein signaling 14 (RGS14) is expressed pre- and postsynaptically in neurons of hippocampus, basal ganglia, and amygdala of monkey and human brain.

Squires KE, Gerber KJ, Pare JF, Branch MR, Smith Y, Hepler JR.

Brain Struct Funct. 2018 Jan;223(1):233-253. doi: 10.1007/s00429-017-1487-y. Epub 2017 Aug 3.

6.

Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks.

Squires KE, Young B, Santiago L, Dretler RH, Walmsley SL, Zhao HH, Pakes GE, Ross LL, Shaefer MS.

HIV AIDS (Auckl). 2017 Mar 3;9:51-61. doi: 10.2147/HIV.S108756. eCollection 2017.

7.

Human Bacterial Artificial Chromosome (BAC) Transgenesis Fully Rescues Noradrenergic Function in Dopamine β-Hydroxylase Knockout Mice.

Cubells JF, Schroeder JP, Barrie ES, Manvich DF, Sadee W, Berg T, Mercer K, Stowe TA, Liles LC, Squires KE, Mezher A, Curtin P, Perdomo DL, Szot P, Weinshenker D.

PLoS One. 2016 May 5;11(5):e0154864. doi: 10.1371/journal.pone.0154864. eCollection 2016.

8.

Roles for Regulator of G Protein Signaling Proteins in Synaptic Signaling and Plasticity.

Gerber KJ, Squires KE, Hepler JR.

Mol Pharmacol. 2016 Feb;89(2):273-86. doi: 10.1124/mol.115.102210. Epub 2015 Dec 11. Review.

9.

Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine.

Young B, Squires KE, Tashima K, Henry K, Schneider S, LaMarca A, Zhao HH, Ross LL, Shaefer MS.

HIV Clin Trials. 2015 Aug;16(4):125-9. doi: 10.1179/1528433614Z.0000000017. Epub 2015 Jul 2. No abstract available.

PMID:
26133089
10.

Story retelling by bilingual children with language impairments and typically developing controls.

Squires KE, Lugo-Neris MJ, Peña ED, Bedore LM, Bohman TM, Gillam RB.

Int J Lang Commun Disord. 2014 Jan-Feb;49(1):60-74. doi: 10.1111/1460-6984.12044. Epub 2013 Aug 31.

11.

Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women.

Kahn JA, Xu J, Kapogiannis BG, Rudy B, Gonin R, Liu N, Wilson CM, Worrell C, Squires KE.

Clin Infect Dis. 2013 Sep;57(5):735-44. doi: 10.1093/cid/cit319. Epub 2013 May 10.

12.

Bone health and human immunodeficiency virus infection.

Schafer JJ, Manlangit K, Squires KE.

Pharmacotherapy. 2013 Jun;33(6):665-82. doi: 10.1002/phar.1257. Epub 2013 Apr 1. Review.

PMID:
23553497
13.

Cobicistat: a new boost for the treatment of human immunodeficiency virus infection.

Shah BM, Schafer JJ, Priano J, Squires KE.

Pharmacotherapy. 2013 Oct;33(10):1107-16. doi: 10.1002/phar.1237. Epub 2013 Mar 7. Review.

PMID:
23471741
14.

Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.

Squires KE, Bekker LG, Eron JJ, Cheng B, Rockstroh JK, Marquez F, Kumar P, Thompson M, Campo RE, Mounzer K, Strohmaier KM, Lu C, Rodgers A, Jackson BE, Wenning LA, Robertson M, Nguyen BY, Sklar P; REALMRK Investigators.

AIDS Res Hum Retroviruses. 2013 Jun;29(6):859-70. doi: 10.1089/AID.2012.0292. Epub 2013 Feb 26.

15.

ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine.

Squires KE, Young B, DeJesus E, Bellos N, Murphy D, Ward D, Zhao HH, Ross LL, Shaefer MS; ARIES Study Team.

HIV Clin Trials. 2012 Sep-Oct;13(5):233-44. doi: 10.1310/hct1305-233.

PMID:
23134624
16.

Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.

Young B, Squires KE, Ross LL, Santiago L, Sloan LM, Zhao HH, Wine BC, Pakes GE, Margolis DA, Shaefer MS; Aries EPZ108859 Study Team.

AIDS Res Hum Retroviruses. 2013 Feb;29(2):350-8. doi: 10.1089/AID.2012.0278. Epub 2012 Dec 5.

17.

Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.

Kahn JA, Burk RD, Squires KE, Kapogiannis BG, Rudy B, Xu J, Gonin R, Liu N, Worrell C, Wilson CM.

J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):390-9. doi: 10.1097/QAI.0b013e3182676fe3.

18.

Prevalence of obstructive lung disease in HIV population: a cross sectional study.

Hirani A, Cavallazzi R, Vasu T, Pachinburavan M, Kraft WK, Leiby B, Short W, Desimone J, Squires KE, Weibel S, Kane GC.

Respir Med. 2011 Nov;105(11):1655-61. doi: 10.1016/j.rmed.2011.05.009. Epub 2011 Jun 23.

19.

Health needs of HIV-infected women in the United States: insights from the women living positive survey.

Squires KE, Hodder SL, Feinberg J, Bridge DA, Abrams S, Storfer SP, Aberg JA.

AIDS Patient Care STDS. 2011 May;25(5):279-85. doi: 10.1089/apc.2010.0228. Epub 2011 Mar 29.

20.

A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen.

Hammer SM, Ribaudo H, Bassett R, Mellors JW, Demeter LM, Coombs RW, Currier J, Morse GD, Gerber JG, Martinez AI, Spreen W, Fischl MA, Squires KE; AIDS Clinical Trials Group (ACTG) 372A Study Team.

HIV Clin Trials. 2010 Nov-Dec;11(6):312-24. doi: 10.1310/hct1106-312.

21.

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.

Squires KE, Johnson M, Yang R, Uy J, Sheppard L, Absalon J, McGrath D.

J Antimicrob Chemother. 2011 Feb;66(2):363-70. doi: 10.1093/jac/dkq457. Epub 2010 Dec 9.

22.

Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus.

Schafer JJ, Short WR, Squires KE.

Pharmacotherapy. 2010 Oct;30(10):1072-83. doi: 10.1592/phco.30.10.1072.

PMID:
20874044
23.

Letter in response to the new SHEA guideline for healthcare workers with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus.

Saag MS, Squires KE, Aberg JA, Bardeguez A.

Infect Control Hosp Epidemiol. 2010 Oct;31(10):1092-3; author reply 1093-5. doi: 10.1086/656559. No abstract available.

PMID:
20812818
24.

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.

Squires KE, Young B, Dejesus E, Bellos N, Murphy D, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS; ARIES study team.

AIDS. 2010 Aug 24;24(13):2019-27. doi: 10.1097/QAD.0b013e32833bee1b.

PMID:
20613461
25.

Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.

Squires KE, Young B, DeJesus E, Bellos N, Murphy D, Sutherland-Phillips DH, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS; ARIES Study Team.

HIV Clin Trials. 2010 Mar-Apr;11(2):69-79. doi: 10.1310/hct1102-69.

PMID:
20542844
26.

Integrase inhibitors: a novel class of antiretroviral agents.

Schafer JJ, Squires KE.

Ann Pharmacother. 2010 Jan;44(1):145-56. doi: 10.1345/aph.1M309. Epub 2009 Dec 29. Review.

PMID:
20040702
27.

Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy.

Fife KH, Wu JW, Squires KE, Watts DH, Andersen JW, Brown DR.

J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):274-82. doi: 10.1097/QAI.0b013e3181a97be5.

28.

HIV policy: the path forward--a joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians.

Lubinski C, Aberg J, Bardeguez AD, Elion R, Emmanuel P, Kuritzkes D, Saag M, Squires KE, Weddle A, Rainey J, Zerehi MR, Ralston JF, Fleming DA, Bronson D, Cooke M, Cutler C, Ejnes Y, Gluckman R, Liebow M, Musana K, Mayer ME, Purtle MW, Reynolds PP, Viswanathan L, Weiss KB, Yehia B.

Clin Infect Dis. 2009 May 15;48(10):1335-44. No abstract available.

PMID:
19385087
29.

HIV infection in women: do sex and gender matter?

Belden KA, Squires KE.

Curr Infect Dis Rep. 2008 Sep;10(5):423-31.

PMID:
18687207
30.

The costs of HIV antiretroviral therapy adherence programs and impact on health care utilization.

Sansom SL, Anthony MN, Garland WH, Squires KE, Witt MD, Kovacs Andrea A, Larsen RA, Valencia R, Pals SL, Hader S, Weidle PJ, Wohl AR.

AIDS Patient Care STDS. 2008 Feb;22(2):131-8. doi: 10.1089/apc.2006.0216.

PMID:
18260804
31.

Gender differences in the diagnosis and treatment of HIV.

Squires KE.

Gend Med. 2007 Dec;4(4):294-307.

PMID:
18215722
32.

Factors influencing the acceptance of changes in antiretroviral therapy among HIV-1-infected patients.

Campo RE, Narayanan S, Clay PG, Dehovitz J, Johnson D, Jordan W, Squires KE, Sajjan SG, Markson LE.

AIDS Patient Care STDS. 2007 May;21(5):329-38.

PMID:
17518525
33.

Women and HIV: a population at risk.

Squires KE.

Res Initiat Treat Action. 2007 Winter;12(2):18-20. No abstract available.

PMID:
17489118
34.

Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.

Gulick RM, Lalama CM, Ribaudo HJ, Shikuma CM, Schackman BR, Schouten J, Squires KE, Koletar SL, Pilcher CD, Reichman RC, Klingman KL, Kuritzkes DR.

AIDS. 2007 Apr 23;21(7):813-23.

PMID:
17415036
35.

Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.

Kuritzkes DR, Ribaudo HJ, Squires KE, Koletar SL, Santana J, Riddler SA, Reichman R, Shikuma C, Meyer WA 3rd, Klingman KL, Gulick RM; ACTG A5166s Protocol Team.

J Infect Dis. 2007 Apr 15;195(8):1169-76. Epub 2007 Mar 6.

PMID:
17357053
36.

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.

Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA 3rd, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR; AIDS Clinical Trials Group (ACTG) A5095 Study Team.

JAMA. 2006 Aug 16;296(7):769-81.

PMID:
16905783
37.

Editorial comment: women and HIV--a population at risk.

Squires KE.

AIDS Read. 2006 Jul;16(7):374-5. No abstract available.

PMID:
16874917
38.

Editorial comment: HIV-infected women require a range of specialized services.

Squires KE.

AIDS Read. 2005 Aug;15(8):426. No abstract available.

PMID:
16114128
39.

Gender-specific considerations in the antiretroviral management of HIV-infected women.

Clark RA, Squires KE.

Expert Rev Anti Infect Ther. 2005 Apr;3(2):213-27. Review.

PMID:
15918779
40.

Incidence and risk factors for sexually transmitted infections among women in an Alabama HIV clinic.

Monteiro CA, Bachmann LH, Desmond RA, Squires KE, Vermund SH, Hook EW, Schwebke JR, Hoesley CJ.

AIDS Res Hum Retroviruses. 2004 Jun;20(6):577-83.

PMID:
15242532
41.

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA 3rd, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR; AIDS Clinical Trials Group Study A5095 Team.

N Engl J Med. 2004 Apr 29;350(18):1850-61.

42.

Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).

Vogler MA, Teppler H, Gelman R, Valentine F, Lederman MM, Pomerantz RJ, Pollard RB, Cherng DW, Gonzalez CJ, Squires KE, Frank I, Mildvan D, Mahon LF, Schock B; AIDS Clinical Trials Group 248 Study Team.

J Acquir Immune Defic Syndr. 2004 May 1;36(1):576-87.

PMID:
15097300
43.

A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir.

Hammer SM, Bassett R, Squires KE, Fischl MA, Demeter LM, Currier JS, Mellors JW, Morse GD, Eron JJ, Santana JL, DeGruttola V; ACTG 372B/D Study Team.

Antivir Ther. 2003 Dec;8(6):507-18. No abstract available.

PMID:
14760884
44.

Once-daily antiretroviral therapies for HIV infection: Consensus Statement of an Advisory Committee of the International Association of Physicians in AIDS Care.

Cohen C, Elion RA, Frank I, Kloser P, Sherer R, Squires KE, Steinhart C, Tebas P; Advisory Committee of the International Association of Physicians in AIDS Care.

J Int Assoc Physicians AIDS Care (Chic). 2002 Oct-Dec;1(4):141-5. Review.

PMID:
12942673
45.

Treating HIV infection and AIDS in women.

Squires KE.

AIDS Read. 2003 May;13(5):228-34, 239-40. Review. No abstract available.

PMID:
12800826
46.

Serum albumin is a powerful predictor of survival among HIV-1-infected women.

Feldman JG, Gange SJ, Bacchetti P, Cohen M, Young M, Squires KE, Williams C, Goldwasser P, Anastos K.

J Acquir Immune Defic Syndr. 2003 May 1;33(1):66-73.

PMID:
12792357
47.

Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.

DiCenzo R, Forrest A, Squires KE, Hammer SM, Fischl MA, Wu H, Cha R, Morse GD; Adult AIDS Clinical Trials Group Protocol 368/886 Study Team.

Antimicrob Agents Chemother. 2003 Jun;47(6):1929-35.

48.

Current management challenges in HIV: antiretroviral resistance.

Kuritzkes DR, Boyle BA, Gallant JE, Squires KE, Zolopa A.

AIDS Read. 2003 Mar;13(3):133-5, 138-42.

PMID:
12728868
49.

Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women.

Viscidi RP, Ahdieh-Grant L, Clayman B, Fox K, Massad LS, Cu-Uvin S, Shah KV, Anastos KM, Squires KE, Duerr A, Jamieson DJ, Burk RD, Klein RS, Minkoff H, Palefsky J, Strickler H, Schuman P, Piessens E, Miotti P.

J Infect Dis. 2003 Jan 15;187(2):194-205. Epub 2003 Jan 6.

PMID:
12552444
50.

A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: correlations with CD4 cell count and plasma HIV-1 RNA level.

Wright PW, Hoesley CJ, Squires KE, Croom-Rivers A, Weiss HL, Gnann JW Jr.

Clin Infect Dis. 2003 Jan 15;36(2):207-11. Epub 2003 Jan 6.

PMID:
12522754

Supplemental Content

Loading ...
Support Center